The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

49 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-08-31

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Individuals with a deficiency of alpha-1 antitrypsin (AAT) often develop emphysema. Traditional lung function tests may not be the most accurate way to measure the progression of emphysema. This study will compare high resolution computed tomography (CT) scans to spirometry to measure the progression of emphysema.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

NCT05297812

Alpha 1-Antitrypsin Deficiency Genetic Disease

ACTIVE_NOT_RECRUITING

Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)

NCT01419158

Alpha-1 Antitrypsin Deficiency Chronic Obstructive Pulmonary Disease

COMPLETED

Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals

NCT00001462

Emphysema Lung Diseases, Obstructive Alpha 1-Antitrypsin Deficiency

COMPLETED

Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease

NCT04966221

Chronic Obstructive Pulmonary Disease Alpha 1-Antitrypsin Deficiency

UNKNOWN

Alpha1-antitrypsin Deficiency Registry

NCT00005292

Lung Diseases Emphysema Alpha-1 Antitrypsin Deficiency +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AAT deficiency is a genetic disorder associated with emphysema. Spirometry, the lung function test that measures how well the lungs exhale air, is used to diagnose and track the progression of emphysema. Some studies have suggested that forced expiratory volume in 1 second (FEV1) measurements, a type of spirometry test, may lack accuracy in detecting disease progression in cases of severe AAT deficiency. Another method, high resolution chest CT scans, may be more accurate at measuring the progression of emphysema. The purpose of this study is to determine if high resolution CT scans are better at detecting the progression of emphysema than lung function tests. Results from this study may lead to the development of a more accurate way to assess lung tissue loss and may improve the understanding of lung destruction in AAT deficiency.

This study will last 4 years and will enroll people with AAT deficiency who have nearly normal lung function test results. Study visits, each lasting about 4 hours, will occur at baseline and months 6, 12, 18, 24, and 36. At each visit, participants will undergo lung function tests, a CT scan, blood collection, and a physical exam. Female participants will have urine collected for a pregnancy test. All participants will also complete questionnaires to assess health status and lung function. Study researchers will call participants every 2 months to collect information on lung disease symptoms and medication changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alpha-1 Antitrypsin Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of AAT deficiency, as determined by both of the following conditions:

1. Serum A1-P1 levels less than 11uM or 80 mg/dL
2. Protease inhibitor phenotype Z (PiZZ) or Znull phenotype confirmed by gene probe analysis. Previous serum levels and phenotype results are acceptable if documented from a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.
* FEV1 greater than or equal to 80% of the predicted value

Exclusion Criteria

* Pregnant or intending to become pregnant within 4 years of study entry
* Previous lung transplantation
* Sibling of a participant who is already enrolled in the study
* Unable to attend scheduled clinic visits
* Currently smokes cigarettes or marijuana or quit smoking cigarettes or marijuana in the 1 year prior to study entry
* Current or planned use of oral tobacco products or nicotine replacement products
* Evidence of significant long-term or acute inflammation outside the lung, including connective diseases, panniculitis, or acute infection
* Unwilling to alter bronchodilator medications for 24 hours prior to scheduled quantitative CT (QCT) scans
* Musculoskeletal disease that limits exercise by walking
* Required to take any of the following medications within 48 hours of scheduled lung function testing: dicyclomine (Bentyl), propantheline (Pro-Banthine), mepenzolate (Cantil), methscopolamine (Pamine), and scopolamine (Transderm-Scop)
* Known allergy or intolerance to tiotropium or albuterol

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No